Abstract
we determined whether these mutations influenced response to single agent and combination PI3K/MEK inhibitors buparlisib and selumetinib, respectively, to elucidate the utility of PIK3-CA mut as a predictive biomarker.
Buparlisib (BKM120) has been proposed as a potential targeted therapy for GBM [30] [31] [32] [33] . It is currently being investigated in a Phase II clinical trial in GBM patients (ClinicalTrials.gov, NCT01339052). While there have been no GBM clinical trials of selumetinib, we and others have shown its efficacy in preclinical models [34, 35] . Enriching future clinical trials with likely responders based on mutational profiles promises to improve the chances of clinical success.
Materials and methods

Supplement
Supplemental methods, figures, and tables can be found online.
PIK3CA mutagenesis and lentivirus production
Third generation lentiviral gateway destination vector (pLenti-PGK-Hygro-DEST, #19066, a gift from Eric Campeau and Paul Kaufman), pENTR4 vector (pENTR4-no-ccDB, #17424, a gift from Eric Campeau and Paul Kaufman), hemagglutinin (HA)-tagged wild-type (WT) PIK3CA (PIK3CA
WT
, pBabe-puro-HAPIK3CA, #12522, a gift from Jean Zhao), and HAtagged GFP (GFP, pDEST-Flag-HA-GFP, #22612, a gift from Wade Harper) plasmids were purchased from Addgene (Cambridge, MA) [36] [37] [38] . Wild-type PIK3CA (PIK3CA
) and GFP were excised and inserted into pENTR4 vector by ligation. PIK3CA mut (R88Q, C90Y, E542K, E545K, M1043V, H1047R) were generated by point mutagenesis of PIK3CA WT using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA) per manufacturer's instructions. GFP, PIK3CA WT , and PIK3CA mut were transferred from pENTR4 to pLenti-PGK-Hygro-DEST vectors by recombination as described [36] . All mutations were confirmed by Sanger sequencing (Genewiz, South Plainfield, NJ). Lentiviral particles encoding GFP, PIK3CA WT , or individual PIK3CA mut were generated in 293FT cells (Invitrogen, Grand Island, NY) per manufacturer's instructions.
Cell culture
NHA and NHA RAS lines were a kind gift from Russell O. Pieper [25] . Cells were maintained as adherent cultures at 37˚C and 5% CO 2 in DMEM supplemented with 5% FBS and 1% penicillin/streptomycin (complete DMEM). To generate NHA and NHA RAS lines expressing GFP,
PIK3CA
WT , or PIK3CA mut , 135,000 and 120,000 cells respectively were plated on 60 cm 2 plates.
Lentiviruses were added two days after plating, then incubated with cells overnight in complete DMEM containing 8 μg/ml polybrene (Sigma-Aldrich, St. Louis, MO) at 37˚C and 5% CO 2 . Two days post-infection, transduced cells were selected by culture in complete DMEM plus 300 μg/ml hygromycin B (Gold Biotechnology, St. Louis, MO) for 14 days. Stable gene expression was confirmed by immunoblot for the HA tag on PIK3CA wt and PIK3CA mut . All in vitro experiments were performed in DMEM with 2.5% FBS and 1% penicillin/streptomycin (low serum medium) unless otherwise stated.
Drugs
The PI3K inhibitor (PI3Ki) buparlisib (BKM120) and the MEK inhibitor (MEKi) selumetinib (AZD6244) were purchased from MedChem Express (Monmouth Junction, NJ) or Chemietek (Indianapolis, IN) and dissolved in dimethyl sulfoxide (DMSO). In single-dose pharmacokinetics studies in human patients, maximum observed plasma concentrations for buparlisib and selumetinib were 2-5 μM (1-2 μg/mL) and 1.1-2.0 μM (0.5-0.9 μg/mL), respectively [39, 40] . Depending on experimental requirements, drugs were used at or above these clinically relevant dose ranges.
Immunoblots
Control (parental, GFP, and PIK3CA
WT
) and PIK3CA mut NHA and NHA RAS cells were treated with either vehicle control (DMSO), buparlisib and/or selumetinib, or serum starved for 24 h. Proteins were isolated and immunoblots were performed as described [19, 24, 35] . Raw immunoblot images are shown in Supplemental Immunoblots. Each blot included both a molecular weight ladder and a reference standard composed of lysates of cultured TRP astrocytes. Quantification was performed using the following formula, where x is an individual blot and i is the [19, 24, 35] . N = 1-3 blots, mean is denoted in the corresponding figure legend. Bands annotated in red are omitted from final figures.
Cell growth
NHA and NHA RAS were plated in triplicate or quadruplicate in 96-well tissue culture plates and absorbance (cell growth) was assessed using CellTiter 96 Aqueous One Cell Proliferation Assay (MTS, Promega, Madison, WI) according to manufacturer's instructions. Relative absorbance was measured daily as described and fit to an exponential growth equation to calculate rate constants (k) and doubling times [ln(2)/k]. Differences in growth rate constants (k) were compared using the extra-sum-of-squares F test [35] .
Cell migration
Migration rate across a cell-free gap was determined using culture inserts according to manufacturer's instructions (Ibidi, Munich, Germany). Briefly, cells were imaged every 2 hours for 12 hours after creation of a cell free gap using a VistaVision inverted microscope equipped with a 4X objective and a DV-300 camera (VWR, Radnor, PA). Gap closure rates were calculated from 2-12 hours using linear regression and compared via ANCOVA.
Colony formation in soft agar
Colony formation was determined as described with minor modifications [25, 41, 42] . Briefly, cells were suspended in a mixture of DMEM/0.35% agarose (Denville Scientific INC., Holliston, MA) supplemented with 2.5% FBS and 14,000 cells were plated per well in 6-well plates. Cells were maintained for 4 weeks, fixed, and stained with 0.005% crystal violet in 70% ethanol.
Plates were imaged on a Typhoon Trio (GE Healthcare) and colonies ! 30 μm 2 were counted.
Mouse use
This study was carried out in strict accordance with the recommendation of the Guide for the Care H1047R NHA RAS cells were injected into the right basal ganglia of mice (N = 5-10 per group, mean = 9) using the coordinates 1, -2, and -4 mm (A, L, D) from bregma as previously described [19, 24] . Subjects received bupivacaine for local nerve block and a single dose of ketorolac for post-surgical analgesia. Animals were monitored daily for the onset of neurological symptoms (lethargy, hunching, seizures, paralysis, loss of righting reflex) and euthanized via CO 2 asphyxiation within 24 hours of onset, immediately followed by brain tissue harvest. Symptoms were frequently severe at first observation due to rapid tumor progression. Animals did not die without euthanasia. Survival was determined by Kaplan-Meier analyses and was compared by log-rank tests.
Drug response
Dose response assays using MTS were performed and IC 50 calculated as described [24, 35] . Synergy between MEKi and PI3Ki was determined by BLISS using Combenefit v1.31 [43] .
Statistics
GraphPad Prism (La Jolla, CA) was used for statistical analyses. Error bars are SEM unless otherwise stated. P 0.05 were considered significant.
Results
PIK3CA
mut are frequent in GBM and are heterogeneously distributed across multiple encoded protein domains, including ABD, helical, and kinase (S1A Fig) [15, 16] . PTEN deletion or activating AKT mutations cooperate with activated MAPK signaling (hereafter MAPK) to promote tumorigenesis in preclinical glioma models [19, 22] . However, the role of PIK3CA mut in has not been examined in these models. To this end, we examined the 2 most frequent (hotspot) helical (E542K, E545K) and kinase (M1043V, H1047R) domain PIK3CA mut found in GBM and other cancer types (S1A- S1C Fig) . ABD mutations are less prevalent in most cancers. Of these, R88Q is the most common and only recurrent mutation in GBM [4, 15] . We therefore evaluated it, as well as a second, C90Y. Neither PIK3CA WT nor ABD PIK3CA mut significantly activated proximal (pAKT) or distal (pS6) PI3K in serum-starved NHA (Fig 1A-1C) . In contrast, E542K and H1047R significantly induced proximal and all 4 helical/kinase mutations induced distal PI3K. We previously showed that mutant Kras cooperates with Pten deletion to activate PI3K in immortalized mouse astrocytes [19] . Therefore, we also determined the effects of PIK3CA mut on PI3K in NHA
RAS
.
PIK3CA
WT and all PIK3CA mut increased proximal PI3K compared to parental NHA RAS (Fig 1D and 1E) . Furthermore, helical and kinase PIK3CA mut potentiated proximal PI3K more than PIK3CA WT . However, distal PI3K was only increased by M1043V in Representative immunoblots (A) and quantification showed that proximal PI3K (pAKT) was increased by helical and kinase mutants in NHA (B). Distal PI3K (pS6) was only increased by H1047R (C) ( Ã , P 0.02). E542K and H1047R increased proximal PI3K and all helical and kinase mutants increased distal PI3Kcompared to PIK3CA
WT NHA ( ‡, P 0.04). Representative immunoblots (D) and quantification showed that proximal PI3K was increased by PIK3CA WT and all mutants (E). Helical and kinase mutants also increased proximal PI3K compared to PIK3CA WT NHA RAS ( ‡, P 0.007). Only M1043V increased distal PI3K compared to parental ( Ã , P = 0.03) and PIK3CA WT ( ‡, P = 0.03) NHA RAS (F). Bar graph data are set relative to parental lines (N = 4 biologic replicates). Fold changes in pAKT and pS6 relative to PIK3CA
WT are shown as heatmaps.
https://doi.org/10.1371/journal.pone.0200014.g001
PIK3CA mutations in glioblastoma NHA RAS (Fig 1D and 1F , particularly helical and kinase mutants, activated PI3K, suggesting that they may also promote cell growth (Fig 1) . MTS assays using high-serum (10% FBS) showed that PIK3-CA WT and a subset of PIK3CA mut slightly increased growth rate ( 15%) of rapidly-proliferating NHA (doubling times 1 day; S4 Fig) . We therefore hypothesized that growth factor concentrations in high-serum media were masking the effects of PIK3CA mut on NHA growth.
Indeed, MTS assays using low-serum (2.5% FBS) revealed increased proliferation of both GFP and PIK3CA WT NHA compared to parental cells (Fig 2A and S5A Fig) . While all PIK3CA mut except C90Y increased proliferation compared to parental and PIK3CA WT NHA, proliferation rates were similar in all NHA RAS lines (Fig 2B and S5B Fig) . Taken together, these data suggest that PIK3CA mut promote astrocyte growth in the absence, but not presence, of mutant RAS.
PIK3CA mut induce migration in vitro
Complete surgical resection of GBM is precluded by its diffuse brain infiltration [45] . The PI3K pathway has an established role in migration [46] . We previously showed that Pten deletion increased migration of immortalized mouse astrocytes [19] . We therefore determined the effects of PIK3CA mut on migration of NHA and NHA RAS using an in vitro gap closure assay.
GFP, PIK3CA
WT and all PIK3CA mut showed increased migration compared to parental NHA (Fig 2C and S5C Fig) . PIK3CA WT and PIK3CA mut except C90Y migrated faster than GFP NHA (P 0.04). Similarly, PIK3CA mut except C90Y migrated faster than GFP and parental NHA RAS (P 0.006, Fig 2D and S5D Fig) . Moreover, E542K and H1047R PIK3CA mut migrated faster than NHA and NHA RAS overexpressing PIK3CA WT (Fig 2C and 2D ).
PIK3CA mut potentiate cellular transformation and tumorigenesis
Anchorage-independent growth (colony formation in soft agar) is an established marker of cellular transformation [25, 41] . NHA RAS , but not NHA, form colonies in vitro and develop high-grade tumors in orthotopic mouse xenograft models [25] . We therefore first determined whether PIK3CA mut promote NHA colony formation by selecting the most potent mutant in each domain (R88Q, E542K, H1047R) based on their effect on proximal PI3K, proliferation, and migration in NHA (Figs 1 and 2) . Only H1047R induced colony formation relative to GFP and parental NHA (Fig 3A) . Since this was the only mutation to potentiate NHA colony formation, we also tested its effect in NHA RAS . However, no significant increase in colony formation was evident (Fig 3A) .
We PI3Ki efficacy is similar regardless of PIK3CA mut status
Neuro-oncology is transitioning towards precision medicine, wherein tumor mutation profiles are utilized to tailor targeted treatments [8, 47] . Knowing which oncogenic driver mutations (Fig 4A) but tended to be slightly higher in NHA RAS (Fig 4B and S7C Fig) . (Fig 4A and 4B) , they differentially activated PI3K (Fig 1) . We therefore investigated whether PIK3CA mut influence PI3Ki-induced changes in pathway signaling. Buparlisib inhibited proximal (Fig 4C and  4D ) and distal ( S9 Fig) PI3K dose-dependently in control and PIK3CA mut NHA. We and others have shown that PI3Ki induce alternate MAPK activation in preclinical GBM models [35, 44, 48] . Indeed, buparlisib induced dose-dependent increases in MAPK in NHA, regardless of their PIK3CA mut status (Fig 4C and 4E) .
Mutant RAS cooperated with PIK3CA WT and PIK3CA mut to potentiate activation of proximal PI3K (Fig 1) . (Fig 5B and S11C Fig) . Thus, PIK3CA mut and mutant RAS had little to no effect on MEKi sensitivity.
PIK3CA
WT and PIK3CA mut influence MEKi-induced PI3K activation in NHA RAS Selumetinib inhibited MAPK in both control and PIK3CA mut NHA (Fig 5C) and induced dose-dependent decreases in pERK regardless of PIK3CA mut status (Fig 5C and 5D ). We and others have shown that MEKi induces alternate PI3K activation in preclinical GBM models [35, 44, 49] . We extended these findings here, showing that selumetinib potentiated proximal PI3K 1.4-5-fold in control and PIK3CA mut NHA (Fig 5C and 5E ). Induction in NHA was least pronounced with E542K and H1047R, the mutations that most potentiated tumorigenesis in NHA RAS (Fig 3B and 3C) .
Mutant RAS cooperated with PIK3CA WT and PIK3CA mut to promote activation of proximal PI3K (Fig 1) . 
S11B and S11C Fig).
They also cooperated with mutant RAS to prevent MEKi-induced potentiation of proximal PI3K (Fig 5F-5H and S12 Fig) 
Discussion
PIK3CA
mut differentially activate PI3K and promote gliomagenesis
The vast majority of GBM harbor mutations in core PI3K pathway genes and/or upstream RTK [4] . Activation of PI3K via Pten deletion, PIK3R1 mutations, or constitutively active AKT mutants promotes tumorigenesis in glioma models [19] [20] [21] [22] . Here, we determined the effects of ABD, helical, and kinase PIK3CA mut on gliomagenesis. Both helical and kinase PIK3CA mut potentiated PI3K, proliferation, and migration of NHA compared to parental and PIK3CA WT lines (Figs 1   and 2 ), but only H1047R kinase mutation potentiated NHA colony formation (Fig 3A) .
We and others have shown that PI3K activation via Pten deletion or constitutively active AKT cooperates with MAPK activation to potentiate gliomagenesis [19, [22] [23] [24] . We extended these findings here by demonstrating that mutant RAS promoted PIK3CA WT -and PIK3CA mut -induced proximal PI3K (Fig 1) . Unlike in NHA, PIK3CA mut did not increase proliferation of NHA RAS , likely due to the rapid proliferation rate of parental cells (Fig 2A and 2B) . H1047R PIK3CA mut also did not potentiate colony formation of NHA RAS , likely because NHA RAS cells are more aggressive and form colonies more readily and at higher density than NHA cells (Fig 3A) . However, the E542K and H1047R PIK3CA mut potentiated malignancy of NHA RAS in vivo compared to GFP and PIK3CA WT (Fig 3B and 3C) . These results are consistent with previous findings that constitutively active AKT does not enhance proliferation or colony formation of NHA RAS in vitro but promotes tumorigenesis in vivo [22] . These data suggest that E542K and H1047R PIK3-CA mut promote in vivo gliomagenesis equally in the presence, but not absence, of mutant RAS.
In contrast to helical and kinase PIK3CA mutations, ABD PIK3CA mut did not increase PI3K, migration, or colony formation of NHA more than PIK3CA WT (Figs 1-3 (Fig 3B and 3C) 
PIK3CA mut do not influence PI3Ki efficacy
The precision medicine initiative seeks to direct treatment with targeted inhibitors based on tumor mutation profiles [8, 47] . However, this requires an understanding of how oncogenic mutations influence drug response. Mutational activation of kinases can cause oncogene addiction, in which tumor cells become reliant upon the activated signaling pathway(s), and are thus highly sensitive to their inhibition [50] . Additionally, kinase mutations can alter drug affinity, thereby altering efficacy [51] . Buparlisib inhibits purified PIK3CA WT and the most common PIK3CA mut , E542K, E545K, and H1047R, with similar IC 50 [52, 53] . Because these helical and kinase domain PIK3CA mut activated PI3K and promoted gliomagenesis, we hypothesized that they would also increase PI3Ki efficacy. However, higher buparlisib doses were required to ablate PI3K in cells expressing PIK3CA mut , particularly those in the helical and kinase domains, and these mutations did not influence PI3Ki efficacy in vitro (Fig 4) . These results suggest that PIK3CA mut neither induce oncogene addiction nor enhance PI3Ki sensitivity. Whether they influence efficacy of isoform-specific PI3Ki or inhibitors of downstream kinases, such as AKT and mTOR, remains to be determined.
PIK3CA mut influence MEKi-induced PI3K activation and PI3Ki/MEKi synergism
We previously found that buparlisib induced widespread kinome changes, including MAPK activation, in immortalized murine astrocytes with Pten deletion and mutant Kras [35] . We expanded these findings here by demonstrating that buparlisib potentiated MAPK regardless of RAS/PIK3CA mutation status (Fig 4C-4H) . PIK3CA mut also had minimal to no effect on sensitivity of NHA and NHA RAS to MEKi in vitro (Fig 5A and 5B ).
We and others have shown that MEKi promote PI3K in preclinical GBM models [35, 44, 49] . We found that selumetinib increased proximal PI3K in control and PIK3CA mut NHA, and in GFP and parental NHA RAS (Fig 5C-5H) . Interestingly, this increase was not apparent in
PIK3CA
WT and PIK3CA mut NHA RAS (Fig 5F and 5H and S12A and S12C Fig) . The mechanism by which ectopic PIK3CA expression in combination with mutant RAS alters MEKi response is unclear. A mutually inhibitory crosstalk between PI3K and MAPK is mediated by p70S6K in glioma stem cells [44] . MAPK inhibition induces PI3K in non-GBM cell lines via removal of a negative feedback loop on RTK [54] . Similarly, selumetinib induces widespread kinome changes in breast cancer models, including increased expression and activity of multiple RTK [55] . Taken together, these results suggest that PIK3CA WT and PIK3CA mut may cooperate with mutant RAS to alter MEKi-induced dynamic kinome changes, particularly as it pertains to PI3K activation. Dual PI3Ki/MEKi treatment is effective in multiple preclinical GBM models [35, 44, 48, 49] . It remains unclear whether the underlying genetics of these models influence drug synergism. We therefore determined if PIK3CA mut affected PI3Ki/MEKi synergism in the presence and absence of mutant RAS. Consistent with other GBM models, we found that dual buparlisib/selumetinib treatment was synergistic in NHA and NHA RAS lines (Fig 6) 
Conclusion
Defining the role of frequently occurring mutations in GBM pathogenesis and drug response can aid identification of predictive biomarkers. Our results demonstrate that PIK3CA mut differentially promote gliomagenesis and do not predict PI3Ki sensitivity but do impact PI3Ki/ MEKi synergism. . Lollipop plot of PIK3CA missense (green), in-frame deletion (brown), and truncating mutations (black) in GBM (A) and all published TCGA datasets (B). PIK3CA missense mutations investigated here are indicated. PIK3CA point mutations were evident in 10.3% of GBM cases from the TCGA (N = 273), with each mutation investigated here representing 1% of total mutations. Data were downloaded from cBioPortal (http://www.cbioportal.org/) on March 10, 2017. Ribbon diagram of PIK3CA with mutations investigated highlighted (C) (R88Q = light green; C90Y = dark green; E542K = pink; E545K = red; M1043V = purple; H1047R = blue). Model was generated in PyMOL.
Supporting information
(Schrödinger, New York City, NY) using a script downloaded from cBioPortal. 13, 14 (TIF) (Fig 2A and 2B) .
Growth was determined by assessing changes in relative absorbance daily by MTS. Migration of control and PIK3CA mutant NHA (C) and NHA RAS (D) across a gap (Fig 2C and 2D) . 
